drugset
drugset / Trial / NCT00375310

Phase I Study of Gemcitabine, Sorafenib and Radiotherapy in Patients With Unresectable Pancreatic Cancer

NCT00375310 ↗

Phase 1 Completed 27 enrolled Indiana University Amgen · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and tolerability of the combined treatment of Sorafenib (BAY 43-9006) with Gemcitabine and radiotherapy in patients with localized unresectable pancreatic cancer.

Timeline

Start
2006-09
Primary completion
2010-11
Completion
2014-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Sorafenib Small molecule 200 mg Oral
Subject Sorafenib Small molecule 400 mg Oral
Background Gemcitabine Small molecule — Intravenous

Indications

pancreatic adenocarcinoma